Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 2/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.49 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29834737 | 0.92 | NSD2 (0.47) | NSD2EHMT2ALDH1A1PIK3CAKDM1A | |
| SCHEMBL29834627 | 0.89 | NSD2 (0.54) | NSD2EHMT2ALDH1A1PIK3CAKDM1A | |
| SCHEMBL28983513 | 0.82 | PIK3CD (0.49) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL29686088 | 0.82 | PIK3CD (0.49) | PIK3CAEGFRPIK3CDPIK3CBPIK3CG | |
| SCHEMBL29834658 | 0.81 | CNR1 (0.47) | NSD2EHMT2ALDH1A1PIK3CAKDM1A | |
| SCHEMBL24037920 | 0.79 | EHMT2 (0.52) | NSD2EHMT2PIK3CAEGFRPIK3CD | |
| SCHEMBL27145045 | 0.78 | EGFR (0.57) | NSD2PIK3CAEGFRDNMT3APIK3CD | |
| SCHEMBL27145372 | 0.78 | EGFR (0.57) | NSD2EHMT2PIK3CAEGFRDNMT3A | |
| SCHEMBL30264576 | 0.78 | EHMT2 (0.45) | NSD2EHMT2PIK3CAPIK3CDPIK3CB | |
| SCHEMBL31257544 | 0.76 | PIK3CD (0.54) | NSD2PIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2022170043-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398805-A1 | QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF | ERBB2, EGFR, ERBB4 | NSD2 1898/4885EHMT2 4166/4885ALDH1A1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.